Categories: SCHD24

Best Practices in Supporting LGBTQ+ Communities

At The Summit on Cancer Health Disparities 2024, in the session titled “Best Practices in Serving LGBTQ+ Communities,Nakita Venus (they/them) and Elle Brooks (she/they) from Seattle’s LGBTQ Center, delved into the importance of understanding health disparities in the LGBTQ+ community, and subsequently best practices.  

 

This begins by employing non-gendered language and creating a gender-affirming space within organizational settings, mainly focusing on healthcare environments catering to the LGBTQ community. This approach advocates for the utilization of gender-neutral language, such as using “they/them” pronouns and non-specific salutations like “Mx.” instead of “Mr.” or “Ms.” It emphasizes addressing individuals by their names to prevent assumptions about gender. It extends to modifying intake forms and training staff to ensure that every client feels respected and valued, emphasizing the use of visual aids and guides, as well as providing access to LGBTQ-specific resources. 

 

These practices are part of a broader initiative to make health services more inclusive and affirming, reflected in the scenarios provided for training purposes. These scenarios help staff practice gender-affirming language when addressing health concerns, ensuring that their language and actions do not inadvertently cause discomfort or perpetuate stigma. 

 

The presenters also touched on their organizational mission, which promotes self-determination, liberation, and joy among the LGBTQ community. This mission underpins the array of services offered, from health services to community programs, all designed to support the diverse identities within the LGBTQ spectrum. Overall, the presentation emphasized the importance of inclusive practices in fostering an environment where all individuals can feel safe, respected, and cared for, aligning organizational operations with the core values of respect and inclusivity.  

 

Bio: 

Omair Syed, MD, MPH, is a PGY3 Internal Medicine resident at Highland Hospital in Oakland, CA, and future chief resident, who will be applying for Hematology/Oncology fellowship.  

 

Disclosures: 

No disclosures or conflicts of interest

Elaina Harris

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

3 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

3 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

4 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

4 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

4 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

4 months ago